Browsing Tag
biotechnology
69 posts
What’s driving GH Research’s stock spike? FDA IND verdict looms for lead depression candidate
GH Research is set to update investors on its FDA IND filing and Phase 3 launch plans for GH001. Find out what this means for its future in depression treatment.
Cynata Therapeutics (ASX: CYP) completes Phase 2 enrolment for CYP-001 as investors refocus on June 2026 data inflection
Cynata Therapeutics completes Phase 2 enrolment for CYP-001, shifting focus to June 2026 data. Read what this means for strategy, risk, and valuation.
Rigel Pharmaceuticals’ R289 delivers promising phase 1b results in transfusion-dependent MDS
Find out how Rigel Pharmaceuticals, Inc. is advancing R289 for lower-risk myelodysplastic syndrome with promising new phase 1b data—read the latest insights now!
Kala Bio launches $10m registered direct financing amid balance sheet reset and dilution concerns
Find out how Kala Bio’s $10 million at-the-market stock offering under Nasdaq rules is reshaping its balance sheet, dilution risk, and survival strategy.
SciSparc targets quantum-powered bio data analysis with NeuroThera majority acquisition move
Find out how SciSparc is moving into quantum-powered bio data analysis through NeuroThera’s majority acquisition plan and what it could mean for investors.
Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review
Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
Phase 2 trial of Nasus Pharma’s NS002 needle-free epinephrine starts with initial dosing milestone
Find out how Nasus Pharma is advancing NS002, its needle-free intranasal epinephrine candidate, into Phase 2 trials and what it means for emergency allergy care.
Investors watch Nuvalent ahead of pivotal neladalkib ALKOVE-1 topline data in resistant ALK-positive NSCLC
Nuvalent will unveil pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive NSCLC on November 17. Explore why investors believe this readout could redefine targeted lung cancer care.
Salarius Pharmaceuticals raises $7m in underwritten offering to fund merger and R&D pipeline
Find out how Salarius Pharmaceuticals is raising $7 million through a structured equity offering as it funds a merger and next-generation biotech pipeline.